Bellicum Pharma (BLCM) Reports Q3 Loss Per Share of $0.51

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Bellicum Pharma (BLCM) Reports Q3 Loss Per Share of $0.51

Bellicum Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Program Updates

November 9, 2015 4:05 PM EST

Pediatric patients with beta thalassemia, SCID, and Wiskott-Aldrich Syndrome are disease-free following haplo transplant with BPX-501 T cells

Additional details of ongoing BPX-501 trial and adoptive T cell programs to be presented at ASH 2015

HOUSTON--(BUSINESS WIRE)-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the third quarter of 2015 and provided an update on recent developments.

During the third... More